Extracts from Rehmannia glutinosa as a therapeutic agent for multiple sclerosis

A technology of multiple sclerosis and extracts, which can be used in drug combinations, plant raw materials, allergic diseases, etc., and can solve problems such as side effects

Pending Publication Date: 2020-01-17
THE UNIVERSITY OF HONG KONG
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently, immunomodulation and immunosuppression are the...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Extracts from Rehmannia glutinosa as a therapeutic agent for multiple sclerosis
  • Extracts from Rehmannia glutinosa as a therapeutic agent for multiple sclerosis
  • Extracts from Rehmannia glutinosa as a therapeutic agent for multiple sclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0078] Reagent

[0079] Rehmannia glutinosa was purchased from KANG MEI Pharmaceutical Co., Ltd (Guangdong, China). Mouse myelin oligodendrocyte glycoprotein (35-55) peptide (MOG) with a purity of more than 96% (wt / wt) 35-55 , MEVGWYRSPFSRVVHLYRNGK) were purchased from Chinese Peptide Company (Zhejiang, China), Freund’s incomplete adjuvant was from Sigma-Aldrich (St.Louis, MO, USA), Mycobacterium tuberculosis H37RA was from BD Biosciences (Difco, BD), and pertussis toxin From List Biological Laboratories (CA, USA). Percoll gradients were purchased from GE Healthcare Life Sciences (Pittsburgh, PA, USA). Cell surface staining antibodies were obtained from eBioscience (San Diego, CA, USA), including CD45-PE (30-F11), CD3e-FITC (145-2C11), CD4-Pacific Blue (RM4-5), and CD11b-APC (M1 / 70). Primary antibodies to 3-NT and iNOS were obtained from Abcam (Cambridge, UK); Bax, p-p65 Ser536 ,p65,p-IKKα / β Ser176 / 180 , IKKβ, p-IκBα Ser32 , IκBα and GAPDH from Cell signaling Technology...

Embodiment 2

[0137] method

[0138] animal

[0139] Female C57BL / 6N mice (10-14 weeks old) were obtained from the Laboratory Animal Unit of the University of Hong Kong. All animal care and experimental procedures were approved by the University Committee on the Use of Live Animals in Teaching and Research (CULATR). Animals were housed in a pathogen-free environment with a 12-hour dark / light cycle.

[0140] Active EAE induction and drug therapy

[0141] Female C57BL / 6N mice were immunized to actively induce EAE as previously described by the inventors (Li, W., et al., 2018). Briefly, with 200 μg MOG in complete Freund's adjuvant (5 mg / ml, Sigma-Aldrich) 35-55 Inject mice subcutaneously. Pertussis toxin (200 ng, List Biological Laboratories) was injected intravenously on days 0 and 2 (dpi.) after immunization. Daily monitoring of immunized mice was assessed with body weight measurements and clinical scores. To assess clinical severity, EAE symptoms were scored as follows: 0, no clinic...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present application relates to extracts from Rehmannia glutinosa as a therapeutic agent for multiple sclerosis. The present application also relates to the use of a digitalis extract, verbascoside, or a combination of catalpol, verbascoside, motherwoside, and digitoxin D in the manufacture of a medicament for preventing or treating multiple sclerosis in a patient. The present invention also relates to the use of radix rehmanniae extract, verbascoside, or a combination consisting of catalpol, verbascoside, motherwoside, and digitoxin D in the preparation of a medicament for preventing or treating experimental autoimmune encephalomyelitis in a patient.

Description

technical field [0001] The invention discloses compositions and methods for treating multiple sclerosis. Background technique [0002] Multiple sclerosis (MS) is an inflammatory autoimmune disease characterized by focal demyelination, axonal and neuronal damage in the central nervous system (CNS). Currently, immunomodulation and immunosuppression are the main therapeutic strategies for MS, but have severe side effects. Due to the prevalence and poor treatment outcomes of the 2.5 million MS patients worldwide, the majority of MS patients eventually develop disability. The search for new MS treatment strategies is of timely importance. Experimental autoimmune encephalomyelitis (EAE) is a widely adopted animal model that mimics key features of MS, including CNS-directed leukocyte infiltration and induction of an inflammatory microenvironment, which disrupts CNS architecture and leads to progressive paralysis. [0003] Autophagy / mitochondrial autophagy is closely involved in ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7034A61K36/804A61K31/7048A61P37/00A61P25/00
CPCA61K31/7034A61K36/804A61K31/7048A61P37/00A61P25/00A61K2300/00
Inventor 沈剑刚李雯婷
Owner THE UNIVERSITY OF HONG KONG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap